187 related articles for article (PubMed ID: 19059852)
1. Questioning the consensus: managing carrier status results generated by newborn screening.
Miller FA; Robert JS; Hayeems RZ
Am J Public Health; 2009 Feb; 99(2):210-5. PubMed ID: 19059852
[TBL] [Abstract][Full Text] [Related]
2. Clinical obligations and public health programmes: healthcare provider reasoning about managing the incidental results of newborn screening.
Miller FA; Hayeems RZ; Bombard Y; Little J; Carroll JC; Wilson B; Allanson J; Paynter M; Bytautas JP; Christensen R; Chakraborty P
J Med Ethics; 2009 Oct; 35(10):626-34. PubMed ID: 19793944
[TBL] [Abstract][Full Text] [Related]
3. Genetic Counselors' Experience with and Opinions on the Management of Newborn Screening Incidental Carrier Findings.
Leppert K; Bisordi K; Nieto J; Maloney K; Guan Y; Dixon S; Egense A
J Genet Couns; 2018 Dec; 27(6):1328-1340. PubMed ID: 29687313
[TBL] [Abstract][Full Text] [Related]
4. To know or not to know, disclosure of a newborn carrier screening test result for cystic fibrosis.
Vernooij-van Langen AM; Reijntjens S; van der Pal SM; Loeber JG; Dompeling E; Dankert-Roelse JE
Eur J Med Genet; 2013 Apr; 56(4):192-6. PubMed ID: 23352994
[TBL] [Abstract][Full Text] [Related]
5. Disclosing to parents newborn carrier status identified by routine blood spot screening.
Oliver S; Dezateux C; Kavanagh J; Lempert T; Stewart R
Cochrane Database Syst Rev; 2004 Oct; (4):CD003859. PubMed ID: 15495068
[TBL] [Abstract][Full Text] [Related]
6. Parents' responses to receiving sickle cell or cystic fibrosis carrier results for their child following newborn screening.
Ulph F; Cullinan T; Qureshi N; Kai J
Eur J Hum Genet; 2015 Apr; 23(4):459-65. PubMed ID: 25005733
[TBL] [Abstract][Full Text] [Related]
7. Managing misaligned paternity findings in research including sickle cell disease screening in Kenya: 'consulting communities' to inform policy.
Marsh V; Kombe F; Fitzpatrick R; Molyneux S; Parker M
Soc Sci Med; 2013 Nov; 96():192-9. PubMed ID: 24034967
[TBL] [Abstract][Full Text] [Related]
8. Communication of carrier status information following universal newborn screening for sickle cell disorders and cystic fibrosis: qualitative study of experience and practice.
Kai J; Ulph F; Cullinan T; Qureshi N
Health Technol Assess; 2009 Nov; 13(57):1-82, iii. PubMed ID: 19948087
[TBL] [Abstract][Full Text] [Related]
9. Clinical and ethical considerations in managing carrier detection.
Ross LF; Clayton EW
Am J Public Health; 2009 Aug; 99(8):1348-9. PubMed ID: 19542030
[No Abstract] [Full Text] [Related]
10. The ethics of deception in biomedical research.
Sharpe G; Weisstub DN
Health Law Can; 1996 May; 16(4):101-10. PubMed ID: 10173418
[No Abstract] [Full Text] [Related]
11. A systematic review of the effects of disclosing carrier results generated through newborn screening.
Hayeems RZ; Bytautas JP; Miller FA
J Genet Couns; 2008 Dec; 17(6):538-49. PubMed ID: 18956236
[TBL] [Abstract][Full Text] [Related]
12. Genetic screening and ethics: European perspectives.
Chadwick R; ten Have H; Husted J; Levitt M; McGleenan T; Shickle D; Wiesing U
J Med Philos; 1998 Jun; 23(3):255-73. PubMed ID: 9736188
[TBL] [Abstract][Full Text] [Related]
13. Challenging the Current Recommendations for Carrier Testing in Children.
VanNoy GE; Genetti CA; McGuire AL; Green RC; Beggs AH; Holm IA;
Pediatrics; 2019 Jan; 143(Suppl 1):S27-S32. PubMed ID: 30600268
[TBL] [Abstract][Full Text] [Related]
14. Carrier detection and clinical uncertainty: the case for public health ethics.
Miller FA; Hayeems RZ; Robert JS
Am J Public Health; 2009 Aug; 99(8):1349-50. PubMed ID: 19542029
[No Abstract] [Full Text] [Related]
15. [Genomic newborn screening. Perspective from the Ethics Commission of the Spanish Society for Human Genetics. Part II: Ethical, legal and social issues (ELSIs) of the introduction of next generation sequencing technologies in a public health newborn screening program.].
Pàmpols Ros T; Pérez Aytés A; García Sagredo JM; Díaz de Bustamante A; Blanco Guillermo I
Rev Esp Salud Publica; 2022 Mar; 96():. PubMed ID: 35283479
[TBL] [Abstract][Full Text] [Related]
16. Genetic counseling and neonatal screening for cystic fibrosis: an assessment of the communication process.
Ciske DJ; Haavisto A; Laxova A; Rock LZ; Farrell PM
Pediatrics; 2001 Apr; 107(4):699-705. PubMed ID: 11335747
[TBL] [Abstract][Full Text] [Related]
17. Implementing carrier screening for cystic fibrosis outside the clinic: ethical analysis in the light of the personalist view.
Di Pietro ML; Teleman AA; Gonzalez-Melado FJ; Zace D; Di Raimo FR; Lucidi V; Refolo P
Clin Ter; 2018; 169(2):e71-e76. PubMed ID: 29595869
[TBL] [Abstract][Full Text] [Related]
18. Informed choice and public health screening for children: the case of blood spot screening.
Hargreaves KM; Stewart RJ; Oliver SR
Health Expect; 2005 Jun; 8(2):161-71. PubMed ID: 15860056
[TBL] [Abstract][Full Text] [Related]
19. Ethical questions concerning newborn genetic screening.
Esquerda M; Palau F; Lorenzo D; Cambra FJ; Bofarull M; Cusi V; Interdisciplinar En Bioetica G
Clin Genet; 2021 Jan; 99(1):93-98. PubMed ID: 32779199
[TBL] [Abstract][Full Text] [Related]
20. Imparting carrier status results detected by universal newborn screening for sickle cell and cystic fibrosis in England: a qualitative study of current practice and policy challenges.
Parker H; Qureshi N; Ulph F; Kai J
BMC Health Serv Res; 2007 Dec; 7():203. PubMed ID: 18078504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
